Similarly, concurrent CCRT in cervical cancer has been shown to suppress the immune microenvironment in both peripheral blood and tumor tissue by reducing T cell counts, T cell receptor diversity, and PD-1/PD-L1 expression. Here, CD274 is linked to cervical cancer.